274 related articles for article (PubMed ID: 36695097)
21. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
22. Teprotumumab (Tepezza) for Thyroid Eye Disease.
Couch SM
Mo Med; 2022; 119(1):36-41. PubMed ID: 36033157
[TBL] [Abstract][Full Text] [Related]
23. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
[TBL] [Abstract][Full Text] [Related]
24. Thyroid eye disease: Redefining its management-A review.
Jain AP; Jaru-Ampornpan P; Douglas RS
Clin Exp Ophthalmol; 2021 Mar; 49(2):203-211. PubMed ID: 33484076
[TBL] [Abstract][Full Text] [Related]
25. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
26. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
Lin F; Yao Q; Yu B; Deng Z; Qiu J; He R
Int J Clin Pract; 2023; 2023():6638089. PubMed ID: 37588100
[TBL] [Abstract][Full Text] [Related]
27. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
28. A New Era in the Treatment of Thyroid Eye Disease.
Patel A; Yang H; Douglas RS
Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
[TBL] [Abstract][Full Text] [Related]
29. Teprotumumab for the treatment of chronic thyroid eye disease.
Ugradar S; Kang J; Kossler AL; Zimmerman E; Braun J; Harrison AR; Bose S; Cockerham K; Douglas RS
Eye (Lond); 2022 Aug; 36(8):1553-1559. PubMed ID: 34244669
[TBL] [Abstract][Full Text] [Related]
30. Early experience with teprotumumab for chronic thyroid eye disease.
Ozzello DJ; Kikkawa DO; Korn BS
Am J Ophthalmol Case Rep; 2020 Sep; 19():100744. PubMed ID: 32462101
[TBL] [Abstract][Full Text] [Related]
31. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
[TBL] [Abstract][Full Text] [Related]
32. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
Douglas RS
Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
[TBL] [Abstract][Full Text] [Related]
33. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
Teo HM; Smith TJ; Joseph SS
Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
[TBL] [Abstract][Full Text] [Related]
35. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
36. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
[TBL] [Abstract][Full Text] [Related]
38. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.
Wang Y; Patel A; Douglas RS
Ther Clin Risk Manag; 2019; 15():1305-1318. PubMed ID: 31814726
[TBL] [Abstract][Full Text] [Related]
39. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.
Lu TJ; Amarikwa L; Sears CM; Kossler AL
Curr Neurol Neurosci Rep; 2022 Jun; 22(6):313-325. PubMed ID: 35614367
[TBL] [Abstract][Full Text] [Related]
40. Teprotumumab for thyroid eye disease: early response is not required for benefit.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS
Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
